Highlights
- Dr. Mann to moderate session on ‘right-sizing’ thyroid cancer care
- Dr. Jehan recognized for top-rated poster and video on esophagectomy
- 3 faculty experts featured in Continuing the Conversation sessions
Newswise — BUFFALO, N.Y. — Cancer surgery leaders from Roswell Park Comprehensive Cancer Center will share their expertise with other cancer surgeons from around the world during the 2025 annual meeting of the Society of Surgical Oncology at the Tampa Convention Center in Tampa, Florida, March 27-29.
, Chair of Surgical Oncology and Chief of Foregut and Endocrine Surgery at Roswell Park, will discuss how emerging biomarkers can inform the treatment of patients with gastroesophageal junction cancers. “Several agents, including chemotherapy, immunotherapy and targeted agents, can be combined in unique ways to achieve optimal results in both the curative and metastatic setting,” he notes.
He will chair Session 010, , and present “Emerging Biomarkers of Treatment Response” as part of a symposium Thursday, March 27, from 8:20-9:50 a.m. EDT in Ballroom BC, with his presentation from 9:29-9:41 a.m.
Dr. Kukar will also address general surgery residents who want to pursue SSO fellowships, during Session 052, , Thursday, March 27, from 1:50-3:20 p.m. EDT in Room 124-125. His talk, “What It Takes to Successfully Match: Importance of the Interview, How to Structure Applicant Rank List,” takes place from 2:30-2:45 p.m. EDT.
Dr. Mann heads discussion of thyroid cancer care
, Professor of Oncology in the Department of Surgical Oncology, will serve as moderator of Session 109, , Friday, March 28, from 2:35-3:35 p.m. EDT in Ballroom D. The session will consider the extent of surgery in patients with low-risk, well-differentiated thyroid cancer as well as the timing and management of combination therapies in advanced, treatment-resistant or recurrent thyroid cancer, with an emphasis on common management challenges. Dr. Mann will also serve on the Endocrine Disease Site Working Group that will convene during the meeting.
Dr. Jehan honored for top-rated poster and video
, a Roswell Park Surgical Oncology Fellow, will give one poster and one video presentation, both recognized by the SSO as among the best in their categories:
Dr. Jehan will present his SSO Top-Rated Poster, P224, Easel 6 — “,” Thursday, March 27, from 10-10:20 a.m. in the HUB Poster Park.
He will present his SSO Top-Rated Video, 128 — “,” Saturday, March 29, from 10:32-10:38 a.m. in Ballroom A.
Dr. Jehan will present his SSO Top-Rated Poster, P224, Easel 6 — “,” Thursday, March 27, from 10-10:20 a.m. in the HUB Poster Park.
He will present his SSO Top-Rated Video, 128 — “,” Saturday, March 29, from 10:32-10:38 a.m. in Ballroom A.
Additional research abstracts
The work of several Roswell Park fellows will be featured as e-posters:
, Fellow in Surgical Oncology — P411, “Outcomes of Clinically Detected Stage II Melanoma Through Individualized Neoadjuvant (PRADO) Approach at a Single Institution.”
, Fellow in Surgical Oncology — P27, “The Role of Neutrophil in Breast Tumor Microenvironment and Association with Response to Neoadjuvant Therapy”
, MD, Fellow in Surgical Oncology — P367, “Intratumoral Lymphangiogenesis Does Not Correlate with Outcomes in Hepatocellular Carcinoma”
, Fellow in Surgical Oncology — P30, “Tumor Hypoxia Is Associated with Markers of Increased Tumor Aggression and Response to Immunotherapy in ER+/HER2- Breast Cancer Patients”
, Fellow in Surgical Oncology — P6, “Clinical Relevance of Sphingosine 1-Phosphate Receptor 4 (S1PR4) in Breast Cancer Using Bulk and Single-Cell Transcriptome Analysis”
, Fellow in Surgical Oncology — P352, “Degree of Dedifferentiation of Hepatocellular Carcinoma Is Not Associated with Decreased Expression of Sphingosine 1-Phosphate Receptor 2”
Masanori Oshi, MD, Postdoctoral Fellow in Breast Surgery — P1, “Activated Hippo Pathway Is Associated with. Worse Response to Trastuzumab and Survival in HER2-Positive Breast Cancer”
, Fellow in Surgical Oncology — P438, “The Atypical Presentation and Delayed Timing of Anastomotic Leak in Patients Who Undergo Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy”
, Fellow in Surgical Oncology — P411, “Outcomes of Clinically Detected Stage II Melanoma Through Individualized Neoadjuvant (PRADO) Approach at a Single Institution.”
, Fellow in Surgical Oncology — P27, “The Role of Neutrophil in Breast Tumor Microenvironment and Association with Response to Neoadjuvant Therapy”
, MD, Fellow in Surgical Oncology — P367, “Intratumoral Lymphangiogenesis Does Not Correlate with Outcomes in Hepatocellular Carcinoma”
, Fellow in Surgical Oncology — P30, “Tumor Hypoxia Is Associated with Markers of Increased Tumor Aggression and Response to Immunotherapy in ER+/HER2- Breast Cancer Patients”
, Fellow in Surgical Oncology — P6, “Clinical Relevance of Sphingosine 1-Phosphate Receptor 4 (S1PR4) in Breast Cancer Using Bulk and Single-Cell Transcriptome Analysis”
, Fellow in Surgical Oncology — P352, “Degree of Dedifferentiation of Hepatocellular Carcinoma Is Not Associated with Decreased Expression of Sphingosine 1-Phosphate Receptor 2”
Masanori Oshi, MD, Postdoctoral Fellow in Breast Surgery — P1, “Activated Hippo Pathway Is Associated with. Worse Response to Trastuzumab and Survival in HER2-Positive Breast Cancer”
, Fellow in Surgical Oncology — P438, “The Atypical Presentation and Delayed Timing of Anastomotic Leak in Patients Who Undergo Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy”
Talk to the experts in Continuing the Conversation sessions
This year’s SSO annual meeting includes Continuing the Conversation get-togethers that will give participants a chance to ask questions and share information with experts in an informal setting.
Dr. Kukar will be featured in , Thursday, March 27, from 10-10:20 a.m. EDT in the Upper GI/HPB/Colorectal HUB Zone.
Dr. Mann will be featured in , Thursday, March 27, from 10-10:20 a.m. EDT in the Pan-Tumor HUB Zone.
, Assistant Professor of Oncology in the Department of Surgical Oncology, will be featured in , Thursday, March 27, from 10-10:20 a.m. EDT in the Immuno-Oncology HUB Zone.
Dr. Kukar will be featured in , Thursday, March 27, from 10-10:20 a.m. EDT in the Upper GI/HPB/Colorectal HUB Zone.
Dr. Mann will be featured in , Thursday, March 27, from 10-10:20 a.m. EDT in the Pan-Tumor HUB Zone.
, Assistant Professor of Oncology in the Department of Surgical Oncology, will be featured in , Thursday, March 27, from 10-10:20 a.m. EDT in the Immuno-Oncology HUB Zone.
RSS